Table.
Characteristics of Trials From 2014 to 2018 that Led to Cancer Drug Approval by the FDA
| Cancer Subtype | FDA Approvals, n |
Trial Participants, n |
African American Participants, n |
|---|---|---|---|
| Solid cancer | |||
| Total | 45 | 49 349 | 3553 |
| Breast cancer | 9 | 22 075 | 1507 |
| Lung cancer | 8 | 6127 | 237 |
| Skin cancer | 8 | 5135 | 268 |
| Ovarian cancer | 4 | 1356 | 148 |
| Sarcoma | 2 | 1240 | 130 |
| Gastrointestinal cancer | 3 | 1520 | 74 |
| Others/multiple solid cancer | 11 | 11 896 | 1189 |
| Hematologic cancer | |||
| Total | 30 | 12 414 | 1033 |
| Leukemia | 17 | 6890 | 496 |
| Lymphoma | 5 | 756 | 200 |
| Multiple myeloma | 6 | 4155 | 314 |
| Myelodysplastic syndrome | 2 | 613 | 23 |
FDA = U.S. Food and Drug Administration.